Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Back to base pairs: What is the genetic risk for red bloodcell alloimmunization?
Gerritsma JJ, Oomen I, Meinderts S, van der Schoot CE, Biemond BJ, van der Bom JG, Fijnvandraat K; SCORE consortium. Gerritsma JJ, et al. Among authors: oomen i. Blood Rev. 2021 Jul;48:100794. doi: 10.1016/j.blre.2020.100794. Epub 2021 Jan 5. Blood Rev. 2021. PMID: 33451870 Free article. Review.
The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia A.
Oomen I, Verhagen M, Miranda M, Allacher P, Beckers EAM, Blijlevens NMA, van der Bom JG, Coppens M, Driessens M, Eikenboom JCJ, Fijnvandraat K, Hassan S, van Heerde WL, Hooimeijer HL, Jansen JH, Kaijen P, Leebeek FWG, Meijer D, Paul H, Rijpma SR, Rosendaal FR, Smit C, van Vulpen LFD, Voorberg J, Schols SEM, Gouw SC. Oomen I, et al. Front Immunol. 2024 Feb 22;15:1355813. doi: 10.3389/fimmu.2024.1355813. eCollection 2024. Front Immunol. 2024. PMID: 38455035 Free PMC article.
Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysis.
Oomen I, Camelo RM, Rezende SM, Voorberg J, Mancuso ME, Oldenburg J, Carcao M, Matino D, Lillicrap D, Fischer K, Fijnvandraat K, Gouw SC; International Genetic and clinical determinants of the Outcome of Immune Tolerance Induction (GO-ITI) study group. Oomen I, et al. Res Pract Thromb Haemost. 2022 Dec 20;7(1):100020. doi: 10.1016/j.rpth.2022.100020. eCollection 2023 Jan. Res Pract Thromb Haemost. 2022. PMID: 36891524 Free PMC article.
Prediction of the chance of successful immune tolerance induction in persons with severe hemophilia A and inhibitors: a clinical prediction model.
Oomen I, Abdi A, Camelo RM, Callado FMRA, Carvalho LEM, Calcaterra IL, Carcao M, Castaman G, Eikenboom JCJ, Fischer K, Franco VKB, Heymans MW, Leebeek FWG, Lillicrap D, Lorenzato CS, Mancuso ME, Matino D, Di Minno MND, Mohseny AB, Oldenburg J, Rezende SM, Rivard GE, Rydz N, Schols SEM, Voorberg J, Fijnvandraat K, Gouw SC; International Genetic and clinical determinants for the outcome of immune tolerance induction study group. Oomen I, et al. Res Pract Thromb Haemost. 2024 Oct 3;8(7):102580. doi: 10.1016/j.rpth.2024.102580. eCollection 2024 Oct. Res Pract Thromb Haemost. 2024. PMID: 39558913 Free PMC article.
Metabolism of paclitaxel in mice.
Bardelmeijer HA, Oomen IA, Hillebrand MJ, Beijnen JH, Schellens JH, van Tellingen O. Bardelmeijer HA, et al. Among authors: oomen ia. Anticancer Drugs. 2003 Mar;14(3):203-9. doi: 10.1097/00001813-200303000-00003. Anticancer Drugs. 2003. PMID: 12634614